Free Trial
NYSE:TEVA

Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis

Teva Pharmaceutical Industries logo
$16.34 +0.05 (+0.31%)
Closing price 08/8/2025 03:59 PM Eastern
Extended Trading
$16.28 -0.06 (-0.37%)
As of 08/8/2025 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Teva Pharmaceutical Industries Stock (NYSE:TEVA)

Key Stats

Today's Range
$16.08
$16.39
50-Day Range
$15.38
$18.07
52-Week Range
$12.47
$22.80
Volume
9.53 million shs
Average Volume
13.04 million shs
Market Capitalization
$18.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.71
Consensus Rating
Buy

Company Overview

Teva Pharmaceutical Industries Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

TEVA MarketRank™: 

Teva Pharmaceutical Industries scored higher than 59% of companies evaluated by MarketBeat, and ranked 408th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Teva Pharmaceutical Industries has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Teva Pharmaceutical Industries has only been the subject of 4 research reports in the past 90 days.

  • Read more about Teva Pharmaceutical Industries' stock forecast and price target.
  • Earnings Growth

    Earnings for Teva Pharmaceutical Industries are expected to grow by 5.20% in the coming year, from $2.50 to $2.63 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Teva Pharmaceutical Industries is -102.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Teva Pharmaceutical Industries is -102.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Teva Pharmaceutical Industries has a PEG Ratio of 0.96. PEG Ratios around 1 indicate that a company is correctly valued.

  • Price to Book Value per Share Ratio

    Teva Pharmaceutical Industries has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.66% of the outstanding shares of Teva Pharmaceutical Industries have been sold short.
  • Short Interest Ratio / Days to Cover

    Teva Pharmaceutical Industries has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Teva Pharmaceutical Industries has recently increased by 33.99%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Teva Pharmaceutical Industries does not currently pay a dividend.

  • Dividend Growth

    Teva Pharmaceutical Industries does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.66% of the outstanding shares of Teva Pharmaceutical Industries have been sold short.
  • Short Interest Ratio / Days to Cover

    Teva Pharmaceutical Industries has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Teva Pharmaceutical Industries has recently increased by 33.99%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Teva Pharmaceutical Industries has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Teva Pharmaceutical Industries this week, compared to 14 articles on an average week.
  • Search Interest

    Only 25 people have searched for TEVA on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Teva Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Teva Pharmaceutical Industries insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $996,958.00 in company stock.

  • Percentage Held by Insiders

    Only 0.49% of the stock of Teva Pharmaceutical Industries is held by insiders.

  • Percentage Held by Institutions

    54.05% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Teva Pharmaceutical Industries' insider trading history.
Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TEVA Stock News Headlines

One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
See More Headlines

TEVA Stock Analysis - Frequently Asked Questions

Teva Pharmaceutical Industries' stock was trading at $22.04 at the beginning of the year. Since then, TEVA stock has decreased by 25.9% and is now trading at $16.34.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced its earnings results on Wednesday, July, 30th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. The business's revenue was up .3% compared to the same quarter last year.
Read the conference call transcript
.

Top institutional shareholders of Teva Pharmaceutical Industries include Phoenix Financial Ltd. (3.29%), Harel Insurance Investments & Financial Services Ltd. (2.91%), Migdal Insurance & Financial Holdings Ltd. (2.50%) and Geode Capital Management LLC (0.84%). Insiders that own company stock include Roberto Mignone, Mark Sabag, Sven Dethlefs, Eliyahu Sharon Kalif, Richard D Francis, David Matthew Stark, Christine Fox, Amir Weiss, Matthew Shields, Eric Drape, Placid Jover, Vikki L Conway and Eric A Hughes.
View institutional ownership trends
.

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Teva Pharmaceutical Industries investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD) and AT&T (T).

Company Calendar

Last Earnings
7/30/2025
Today
8/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - GENERIC DRG
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:TEVA
CIK
818686
Employees
36,830
Year Founded
1901

Price Target and Rating

High Price Target
$30.00
Low Price Target
$22.00
Potential Upside/Downside
+51.3%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.16)
Trailing P/E Ratio
N/A
Forward P/E Ratio
6.54
P/E Growth
0.96
Net Income
-$1.64 billion
Net Margins
-0.95%
Pretax Margin
-0.45%
Return on Equity
46.10%
Return on Assets
7.18%

Debt

Debt-to-Equity Ratio
2.45
Current Ratio
1.06
Quick Ratio
0.77

Sales & Book Value

Annual Sales
$16.54 billion
Price / Sales
1.13
Cash Flow
$3.38 per share
Price / Cash Flow
4.84
Book Value
$5.96 per share
Price / Book
2.74

Miscellaneous

Outstanding Shares
1,146,960,000
Free Float
1,141,340,000
Market Cap
$18.74 billion
Optionable
Optionable
Beta
0.62

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NYSE:TEVA) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners